Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 13, 2024
Reporting Period: Specific event date (May 13, 2024)
Collegium Pharmaceutical, Inc. is a Virginia corporation with its principal executive offices in Stoughton, MA. The company's common stock trades on the NASDAQ Global Select Market under the symbol "COLL".
Key Financial Metrics and Capital Allocation
This filing reports on a specific capital allocation event rather than periodic financial performance. Key metrics disclosed include:
- Share Repurchase Authorization: $35 million committed under an Accelerated Share Repurchase (ASR) Agreement.
- Counterparty: Jefferies LLC.
- Initial Share Delivery: 888,889 shares received immediately.
- Valuation Basis: Initial delivery based on the $31.50 closing stock price on May 10, 2024.
- Outstanding Shares: Approximately 32.7 million shares as of March 31, 2024.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for the period.
Material Changes and Program Details
The ASR Agreement is part of a broader $150 million share repurchase program authorized by the Board of Directors in January 2024. Material terms include:
- Program Status: The $35 million ASR represents a portion of the total $150 million authorization.
- Settlement Terms: The final number of shares to be repurchased will be determined based on the volume-weighted average prices of the Company's common stock during the term of the agreement.
- Expected Completion: Final settlement is expected in the third quarter of 2024.
- Initial Coverage: The initial delivery of 888,889 shares represents approximately 80% of the total shares expected to be repurchased under this specific ASR Agreement.
Guidance, Outlook, and Risks
Management Commentary: The company views this transaction as a strategic use of capital under the previously authorized program. The filing contains forward-looking statements regarding the share repurchase program and the expected completion date of the ASR.
Risks and Contingencies: Actual results may differ materially from expectations due to factors including:
- Developments or changes in securities markets.
- Fluctuations in trading volume and market price of the Company's common stock.
- Other risks described in the Company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
The Company assumes no obligation to update forward-looking statements after the date of this filing.
Investor Verification Checklist
- Verify the remaining balance of the $150 million share repurchase program authorized in January 2024.
- Monitor the final settlement of the ASR Agreement in Q3 2024 to determine the total number of shares repurchased and the final average price.
- Review the Company's most recent Form 10-Q or 10-K for updated cash position and liquidity metrics to assess the impact of the $35 million cash outflow.
- Confirm the current number of shares outstanding, noting the initial reduction of 888,889 shares.